Agilent Technologies, Inc. reported a net revenue of $1,878 million for the three months ended July 31, 2026, marking an 8% increase compared to $1,738 million in the same period last year. For the nine months ended July 31, 2026, the company achieved a total revenue of $5,511 million, also an 8% rise from $5,087 million in the prior year. The growth was driven by all segments and geographic regions, with notable contributions from the Life Sciences and Diagnostics Markets segment, which saw an 11% increase in revenue for the quarter and a 9% increase for the nine-month period.
The company's net income for the third quarter was $362 million, up from $336 million a year earlier, while net income for the nine months reached $1,006 million, compared to $869 million in the same period last year. The increase in profitability was attributed to higher sales volume, a net benefit from tariff refunds, and lower restructuring expenses, despite facing wage increases and higher variable pay. The operating margin improved to 23.6% for the quarter, up from 20.7% in the previous year, and 21.7% for the nine months, compared to 20.4% last year.
Agilent's strategic developments included the acquisition of BC Midco I, Inc. (Biocare) on June 24, 2026, for $950 million, which is expected to enhance its pathology portfolio. The acquisition has been integrated into Agilent's financials from the date of acquisition. The company also issued $600 million in senior notes on June 25, 2026, which will mature on January 15, 2032, at a fixed interest rate of 4.90%.
Operationally, Agilent's headcount increased to approximately 18,200 as of July 31, 2026, up from 18,000 a year prior, primarily due to the Biocare acquisition. The company reported cash and cash equivalents of $1,758 million, slightly down from $1,789 million at the end of the previous fiscal year. Cash provided by operating activities was $1,064 million for the nine months, compared to $1,014 million in the same period last year. Looking ahead, Agilent remains optimistic about long-term growth prospects, particularly in its key markets, while continuing to monitor the impacts of tariffs and geopolitical tensions on its operations.
About AGILENT TECHNOLOGIES, INC.
Agilent Technologies Inc. is a global leader in life sciences, diagnostics, and applied chemical markets, offering instruments, software, services, and consumables for laboratory workflows. With a focus on enhancing customer outcomes, Agilent targets pharmaceutical, biopharmaceutical, and academic sectors, addressing a $60 billion market opportunity. The company is innovating through advanced manufacturing partnerships and expanding its diagnostics and genomics capabilities, including cell analysis and companion diagnostics, to meet evolving healthcare needs.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.